Medicines | European Medicines Agency

Medicines

For help on how to get the results you want, see our search tips.

Search results

Categories

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

Product number

ATC code

Procedure number

Document regulatory outcome

Medicine type

Related medicine

Therapeutic area

Last updated

First published

6 results

Sort by

List item

Direct healthcare professional communication (DHPC): Systemic and inhaled fluoroquinolones: risk of heart valve regurgitation/incompetence

Active substance: Delafloxacin, levofloxacin, DHPC type: Safety signal, Last updated: 29/10/2020
List item

Direct healthcare professional communication (DHPC): Ondexxya (andexanet alfa): Avoid use of andexanet prior to heparinization

Active substance: andexanet alfa, DHPC type: Adverse event, Last updated: 04/11/2020
List item

Direct healthcare professional communication (DHPC): Prevymis (letermovir) concentrate for solution for infusion - Essential to administer through sterile 0.2 micron or 0.22 micron polyethersulfone (PES) in-line filter

Active substance: Letermovir, Last updated: 11/09/2020
List item

Direct healthcare professional communication (DHPC): Gilenya (fingolimod) - Updated recommendations to minimise the risk of drug-induced liver injury (DILI)

Active substance: Fingolimod, DHPC type: Periodic safety update report, Last updated: 10/11/2020
List item

Direct healthcare professional communication (DHPC): Ondexxya (andexanet alfa): Commercial anti-FXa activity assays are unsuitable for measuring anti-FXa activity following administration of andexanet alfa

Active substance: andexanet alfa, DHPC type: Safety signal, Last updated: 17/06/2020
List item

Direct healthcare professional communication (DHPC): Lojuxta (lomitapide): Reminder to monitor the liver function of patients treated with Lojuxta and to avoid use in pregnancy

Active substance: Lomitapide, DHPC type: Post-authorisation measure, Last updated: 17/02/2021